Acute ischemic stroke (AIS) is a medical emergency caused by decreased blood flow to the brain, which results in damage to brain cells. Acute ischemic stroke is a leading cause of death and disability in the US and affects approximately 7,00,000 people each year. Currently, the AIS domain constitutes an immensely robust pipeline with more than 35+ drugs under different phases of development.DelveInsight brings into focus AIS, its symptoms, and treatment. Additionally, AIS research and developmental activities, pipeline assessment, and key companies are thoroughly covered in this newsletter. Learn more about the recent happenings, ongoing research &amp; development, significant pharmaceutical companies involved in the AIS market, top-notch collaborations anticipated to occur, licensing &amp; fundings, and breakthroughs in the AIS market landscape.Get a sneak peek of the AIS pipeline therapies, clinical trials, deals &amp; tie-ups, and upcoming world-class conferences, as well as track all the recent updates in the AIS market.Interested in knowing more about what upcoming years hold for the AIS market and how pharma companies work to push drug development? Download our Newsletter by simply filling up the form on the right.Stay tuned!

Acute ischemic stroke (AIS) is a medical emergency caused by decreased blood flow to the brain, which results in damage to brain cells. Acute ischemic stroke is a leading cause of death and disability in the US and affects approximately 7,00,000 people each year. Currently, the AIS domain constitutes an immensely robust pipeline with more than 35+ drugs under different phases of development.

Acute Ischemic Stroke (AIS)

Through Acute Ischemic Stroke Newsletter, learn more about the recent happenings, ongoing research & development, significant pharmaceutical companies involved in the Acute Ischemic Stroke treatment market, top-notch collaborations anticipated to occur, licensing & fundings, and breakthroughs. 